* Biogen Inc., of Cambridge, Mass., said it resolved separate commercial disputes with Rentschler Arzneimittlel GmbH & Co., of Laupheim, Germany; ASTA Medica, of Frankfurt; and CVS pharmacies and others. The impact to Biogen will "not be material," the company said.* Cell Pathways Inc., of Horsham, Pa., filed an investigational new drug application with the FDA to begin Phase I trials of CP461, the company's second investigational drug candidate. After a single-dose safety study in healthy volunteers, Cell Pathways plans to conduct a dose-ranging Phase I/II study of the drug as a potential treatment for cancer.

* Geron Corp., of Menlo Park, Calif., and the University of Texas Southwestern Medical Center at Dallas demonstrated that telomerase expression in normal cells confers an infinite replicative capacity, but does not result in the cellular changes associated with cancer. Telomerase is an "immortalizing" enzyme that imparts infinite replicative capacity to reproductive and cancer cells. The research, to be published in the Jan. 1, 1999 issue of Nature Genetics, showed introducing telomerase into normal cells resulted in extension of their replicative lifespan.

No Comments